Commodore Capital ELVN Position
Active7-Fund ConvergenceCommodore Capital held their position in Enliven Therapeutics, Inc. (ELVN) in Q4 2025, holding $72.3M worth of shares across 4,692,809 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ELVN is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 19.5% of float with 11.3 days to cover, indicating significant bearish positioning against Commodore's long thesis.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Full company profile →Short Interest
19.5%
11.3 days to cover
Commodore Capital ELVN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 4,692,809 | — | $72.3M |
| Q3 2025 | Held | 4,692,809 | — | $96.1M |
| Q2 2025 | Increased | 4,692,809 | +17,809 | $94.1M |
| Q1 2025 | Increased | 4,675,000 | +470,000 | $92.0M |
| Q4 2024 | Increased | 4,205,000 | +105,000 | $94.6M |
| Q3 2024 | Increased | 4,100,000 | +126,755 | $104.7M |
| Q2 2024 | Held | 3,973,245 | — | $92.9M |
| Q1 2024 | Increased | 3,973,245 | +1,071,429 | $69.9M |
| Q4 2023 | Held | 2,901,816 | — | $40.2M |
| Q3 2023 | Increased | 2,901,816 | +553,544 | $39.6M |
| Q2 2023 | Increased | 2,348,272 | +616,907 | $47.9M |
| Q1 2023 | New | 1,731,365 | +1,731,365 | $37.9M |
Frequently Asked Questions
Does Commodore Capital own ELVN?
Yes. As of Q4 2025, Commodore Capital holds 4,692,809 shares of Enliven Therapeutics, Inc. (ELVN) valued at $72.3M. This data comes from their SEC 13F filing.
How many hedge funds own ELVN?
7 specialist biotech hedge funds currently hold ELVN, including OrbiMed Advisors, RA Capital Management, Cormorant Asset Management and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Commodore Capital first buy ELVN?
Commodore Capital's position in ELVN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Commodore Capital's ELVN position increasing or decreasing?
Commodore Capital held their ELVN position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ELVNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Commodore CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →